Valuation: Mirum Pharmaceuticals, Inc.

Market Cap 6.42B 5.59B 5.29B 4.81B 8.98B 615B 9.02B 63B 24.36B 312B 24.1B 23.57B 1T P/E 2026 *
-6.53x
P/E 2027 * -123x
Enterprise Value 6.6B 5.75B 5.44B 4.94B 9.23B 632B 9.28B 64.78B 25.05B 321B 24.78B 24.23B 1,028B EV / Sales 2026 *
9.47x
EV / Sales 2027 * 7.96x
Free-Float
98.34%
Yield 2026 *
-
Yield 2027 * -
1 day+1.49%
1 week-1.78%
Current month+0.79%
1 month-1.01%
3 months-3.16%
6 months+2.35%
Current year+25.10%
1 week 93.57
Extreme 93.57
100.5
1 month 93.57
Extreme 93.57
104.66
Current year 73.82
Extreme 73.82
130
1 year 63.23
Extreme 63.232
130
3 years 23.14
Extreme 23.14
130
5 years 12.82
Extreme 12.82
130
10 years 6.51
Extreme 6.5126
130
Manager TitleAgeSince
Chief Executive Officer 47 2019-03-20
Director of Finance/CFO 66 2023-09-10
President 48 2024-01-15
Director TitleAgeSince
Chairman 73 2019-03-20
Director/Board Member 55 2018-11-06
Director/Board Member 47 2018-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/14/26 Sell

Chief Financial Officer

-9,943 0.0153%
9/2/26 Sell

Controller/Auditor

-658 0.0010%
9/1/26 Exercice

Founder

90,000 0.1386%
Change 5-day change 1-year change 3-year change Capi.($)
+1.49%-1.78%+35.11%+200.82% 6.42B
+1.28%+2.62%+51.61%+100.19% 1,027B
+1.10%+1.45%+52.49%+67.37% 651B
+0.58%+3.54%+19.57%+73.56% 467B
+0.91%+5.98%+39.50%+41.42% 350B
+0.60%+4.21%+20.74%+26.89% 268B
+1.21%+7.46%+11.85%+17.27% 257B
+0.91%-0.70%+38.25%+45.67% 205B
+1.63%+2.82%-27.58%-56.30% 190B
+2.17%+4.20%+34.41%+99.41% 187B
Average +0.68%+2.06%+27.60%+61.63% 360.85B
Weighted average by Cap. +0.15%+2.62%+35.48%+62.58%

Financials

2026 *2027 *
Net sales 697M 607M 574M 522M 975M 66.71B 979M 6.84B 2.64B 33.9B 2.62B 2.56B 109B 816M 711M 673M 611M 1.14B 78.15B 1.15B 8.01B 3.1B 39.72B 3.07B 3B 127B
Net income -933M -813M -769M -699M -1.31B -89.36B -1.31B -9.16B -3.54B -45.41B -3.51B -3.43B -145B -32.99M -28.74M -27.2M -24.71M -46.16M -3.16B -46.39M -324M -125M -1.61B -124M -121M -5.14B
Net Debt 181M 158M 149M 136M 253M 17.33B 254M 1.78B 687M 8.81B 680M 665M 28.19B 74.95M 65.28M 61.79M 56.14M 105M 7.18B 105M 736M 285M 3.65B 282M 275M 11.68B
Logo Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Employees
433
Date Price Change Volume
26-09-17 US$98.82 +1.49% 937,608
26-09-16 US$97.37 +3.70% 991,189
26-09-15 US$93.90 -2.95% 948,708
26-09-14 US$96.75 -1.50% 488,542
26-09-11 US$98.22 -2.38% 441,100
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
98.82USD
Average target price
138.21USD
Spread / Average Target
+39.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MIRM Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!